Clinical trials: Blood Loss,
Blood Loss Massive, Post Partum Hemorrhage
QStat Cartridge in Obstetric Patients
This study will assess the performance of the Quantra System with the QStat Cartridge versus standard of care coagulation testing in pregnant women at risk of bleeding at delivery.
- Trial name
- NCT06255496
- Testing
- Quantra Hemostasis Analyzer with the QStat Cartridge
- Where
- 6 sites in United States
- Volunteers
- 296 people
- Sponsor
- HemoSonics LLC
Post Operative Hemorrhage, Transfusion Related Complication
Monitoring Noninvasively for Infusion and Transfusion Optimization
This is a multicenter, cluster randomized controlled trial to assess the effects of an optimized intraoperative fluid and blood management strategy on postoperative complications.
- Conditions
- Post Operative Hemorrhage, Transfusion Related Complication, Blood Transfusion Associated Adverse Reactions, Hypovolemia
- Trial name
- NCT04388722
- Testing
- Pulse CO-Oximeter Sensor
- Sponsor
- Masimo Corporation
Purpura, Thrombocytopenic, Idiopathic
Pilot Study of Fostamatinib Disodium/R935788 for the Treatment of Adult Refractory Immune Thrombocytopenic Purpura (ITP)
The purpose of this study is to determine whether Fostamatinib Disodium is safe and effective in the treatment of Adult Refractory Immune Thrombocytopenic Purpura (ITP).
- Trial name
- NCT00706342
- Testing
- Fostamatinib Disodium / R935788
- Where
- 2 sites in United States
- Volunteers
- 18 people
- Sponsor
- Rigel Pharmaceuticals
Acquired Thrombotic Thrombocytopenic Purpura
Study to Assess Efficacy and Safety of Anti-von Willebrand Factor (vWF) Nanobody in Patients With Acquired Thrombotic Thrombocytopenic Purpura (aTTP)
This study was a Phase II, single-blind, randomized, placebo-controlled trial to determine whether anti-vWF Nanobody is safe and effective as adjunctive treatment in patients with aTTP.
- Trial name
- TITAN (NCT01151423)
- Testing
- Caplacizumab
- Where
- 51 sites in United States, Australia and 11 more
- Volunteers
- 75 people
- Sponsor
- Ablynx, a Sanofi company
Acquired Thrombotic Thrombocytopenic Purpura
A Clinical Study of Anfibatide in Acquired Thrombotic Thrombocytopenic Purpura (TTP)
This is a multicenter, randomized, double-blind, parallel, placebo-controlled phase II clinical study. It is planned to recruit 74 patients with acquired thrombotic thrombocytopenic purpura (TTP).
- Trial name
- NCT04021173
- Testing
- Anfibatide
- Where
- China
- Volunteers
- 74 people
- Sponsor
- Lee's Pharmaceutical Limited
Esophageal Varices, Portal Hypertension
Use of Sanvar® With Endoscopic Treatment for the Control of Acute Variceal Bleeding
The main objective of this study is to determine the efficacy of early administration of Sanvar® in combination with endoscopic treatment for the control of acute variceal bleeding.
- Conditions
- Esophageal Varices, Portal Hypertension, Gastric Varices, Esophageal Bleeding
- Trial name
- NCT00331188
- Testing
- Sanvar® (vapreotide)
- Where
- 19 sites in United States
- Volunteers
- 70 people
- Sponsor
- Debiovision
Hematuria, Dysuria
Efficacy Study of a Urine DEK ELISA for Diagnosis of Bladder Cancer
The objective of this study is to use a DEK ELISA to quantitatively measure DEK protein in the urine of patients suspected of having bladder cancer.
- Conditions
- Hematuria, Dysuria, Bladder Cancer
- Trial name
- NCT01563796
- Where
- United States
- Volunteers
- 1,115 people
- Sponsor
- Medical Diagnostic Laboratories, LLC
Hemophilia A, Hemophilia B
A Phase 2/ 3 Trial to Evaluate the Efficacy and Safety of BAY86-6150
Haemophilia is a disorder, usually genetic, affecting mostly male individuals, in which one of the proteins needed to form blood clots (FVIII) is missing or not present in sufficient levels.
- Trial name
- NCT01625390
- Testing
- BAY86-6150, eptacog alfa [activated]
- Where
- 61 sites in United States, Australia and 27 more
- Volunteers
- 10 people
- Sponsor
- Bayer
Immune Thrombocytopenia (ITP), ITP
A Phase 1b/2a Study of Budoprutug in Subjects With Immune Thrombocytopenia (ITP)
The main objective is to assess the safety and tolerability of budoprutug in adults with ITP. Pharmacokinetics, pharmacodynamics, and preliminary clinical efficacy will also be assessed.
- Conditions
- Immune Thrombocytopenia (ITP), ITP, Biologics, Monoclonal
- Trial name
- NCT07043946
- Testing
- Budoprutug
- Where
- 20 sites in Bulgaria, Greece and 3 more
- Volunteers
- 24 people
- Sponsor
- Climb Bio, Inc.
Nonvariceal Upper Gastrointestinal Bleeding
Effectiveness of 'Nexpowder' for Hemostatic Treatments of Nonvariceal, Upper Gastrointestinal Bleeding
A prospective, multi-center, randomized controlled trial to evaluate safety and effectiveness of endoscopic hemostatic powder, 'Nexpowder' for hemostatic treatments of nonvariceal upper gastrointestinal bleeding.
- Trial name
- NCT04124588
- Testing
- Nexpowder (Hemostatic powder), Conventional Technique
- Where
- 3 sites in South Korea
- Volunteers
- 348 people
- Sponsor
- Next Biomedical Co., Ltd.
Immune Thrombocytopenia
An Open-label Safety Study of Lusutrombopag (S-888711) in Adults With Chronic Immune Thrombocytopenia (ITP)
The primary objective of this study was to assess the long-term safety of lusutrombopag in the treatment of adults with relapsed persistent or chronic ITP with or without prior splenectomy.
- Trial name
- NCT01129024
- Testing
- Lusutrombopag
- Where
- 19 sites in United States
- Volunteers
- 19 people
- Sponsor
- Shionogi
Cerebral Vasospasm, Aneurysmal Subarachnoid Hemorrhage (aSAH)
Registry on NeVa VS for CerebraL VAsospasm ManagemenT in Post SAH PatiEnts
A multi-center, observational registry study intended to assess the HDE-approved NeVa VS cerebral artery dilation device in patients with symptomatic cerebral vasospasm caused by aneurysmal subarachnoid hemorrhage (aSAH)
- Trial name
- DILATE (NCT06893588)
- Testing
- NEVA VS
- Where
- 16 sites in United States
- Volunteers
- 200 people
- Sponsor
- Vesalio
High Bleeding Risk, Coronary Artery Disease
Management of High Bleeding Risk Patients Post Bioresorbable Polymer Coated Stent Implantation With an Abbreviated Versus Prolonged DAPT Regimen
The study compares two lengths of medication therapy (a shortened versus a prolonged dual antiplatelet therapy) in order to prevent thrombus (blood cloth) formation after the successfully treatment for coronary heart disease with…
- Conditions
- High Bleeding Risk, Coronary Artery Disease, PCI
- Trial name
- MASTER DAPT (NCT03023020)
- Testing
- Aspirin, P2Y12 inhibitor
- Where
- 138 sites in Argentina, Australia and 28 more
- Volunteers
- 4,579 people
- Sponsor
- ECRI bv
Acute Upper Gastrointestinal Hemorrhage, Acute Upper Gastrointestinal Bleeding
Clinical Investigation of Safety and Performance of a Medical Device (ClearPlasma) for the Treatment of Patients With Acute Upper Gastrointestinal Hemorrhage.
Pre-market, multi-center, international, double-blind, randomized, controlled, prospective, first-in-human clinical investigation of a Class IIb Investigational Medical Device, in which Patients presenting with acute upper…
- Trial name
- NCT04174989
- Testing
- Plasma treated with ClearPlasma (Extra-corporeal plasma filtration device), Regular fresh-frozen plasma (not treated)
- Where
- 8 sites in Czechia, Israel and 1 more
- Volunteers
- 53 people
- Sponsor
- PlasFree Ltd.
Hypervascular Tumors, Bleeding
Obsidio™ Conformable Embolic Registry
OCCLUDE is a prospective, post-approval, open-label, single arm, multi-center US registry of patients who undergo embolization with Obsidio™ Conformable Embolic.
- Conditions
- Hypervascular Tumors, Bleeding, Hemorrhage
- Trial name
- OCCLUDE (NCT06170619)
- Testing
- Obsidio™ Conformable Embolic
- Where
- 20 sites in United States
- Volunteers
- 125 people
- Sponsor
- Boston Scientific Corporation
Primary Immune Thrombocytopenia (ITP)
A Study to Assess the Efficacy and Safety of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (ITP)
This is a randomized, double-blind placebo-controlled multicenter phase 3 trial to evaluate the efficacy and safety of ARGX-113 in patients with primary ITP.
- Trial name
- ADVANCE2 (NCT04274452)
- Testing
- efgartigimod
- Sponsor
- argenx
Non Valvular Atrial Fibrillation
Apixaban Versus Rivaroxaban in Non Valvular Atrial Fibrillation
The investigators will first measure the maximum concentration (after 2 hours of intake) and the residual concentration (just before the next intake) after at least 15 consecutive days of treatment.
- Trial name
- APIXA-Xa (NCT06862726)
- Testing
- Anti Xa dosage, Dosage of PT-INR
- Where
- Tunisia
- Volunteers
- 120 people
- Sponsor
- Les Laboratoires des Médicaments Stériles
Thrombotic Thrombocytopenic Purpura (TTP)
A Survey of Recombinant ADAMTS13 in Participants With Congenital Thrombotic Thrombocytopenic Purpura
This study is a survey in Japan of recombinant ADAMTS13 used to treat or to prevent participants with congenital thrombotic thrombocytopenic purpura (cTTP).
- Trial name
- NCT06441578
- Testing
- Recombinant ADAMTS13
- Where
- Japan
- Volunteers
- 40 people
- Sponsor
- Takeda
Spinal Tumor, Spinal Injury
Study of Collagen-Based Thrombin Hemostat for the Control of Bleeding in Spinal Surgery
This clinical trial evaluates the effectiveness and safety of a collagen-based hemostatic agent containing thrombin in patients undergoing spinal surgery.
- Conditions
- Spinal Tumor, Spinal Injury, Hemostasis, Spinal Stenosis
- Trial name
- NCT07354178
- Testing
- CollaStat®, Floseal®
- Where
- 3 sites in South Korea
- Volunteers
- 130 people
- Sponsor
- DALIM TISSEN Co., Ltd.
Cerebral Vasospasm
Vesalio NeVa VS for Symptomatic Cerebral Vasospasm Following aSAH (The VITAL Study)
The objective of the study is to assess the safety and probable benefit of the Neva VS device in patients presenting with symptomatic cerebral vasospasm despite maximal medical management following aSAH.
- Trial name
- NCT03611790
- Testing
- NeVa VS
- Where
- 10 sites in United States
- Volunteers
- 30 people
- Sponsor
- Vesalio
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.